Expected to generate value over 1.64 billion baht for medical laboratory and healthcare.

BANGKOK, THAILAND – Media OutReach Newswire – 10 July 2024 – Informa Markets launched “Medlab Asia & Asia Health 2024,” the largest medical laboratory and medical device trade show and conference in Southeast Asia. Under the concept of International Healthcare Week, it focuses on presenting advancements and innovations in the medical industry, creating opportunities and business networks for entrepreneurs during challenging in the Thai and Asian healthcare industries, and enhancing knowledge for healthcare personnel.

Mr. Manu Leopairote, Chairman of Informa Markets Thailand, stated, “This year, Informa Markets has combined three major events in Southeast Asia: Medlab Asia, Asia Health, and CPHI Southeast Asia, under the concept of International Healthcare Week. This platform is the most important for global health experts to network, learn, and do business, focusing on innovative products and solutions related to medical laboratories, medical devices, health solutions, and the pharmaceutical industry value chain, including academic conferences, seminars, and meetings across all related sectors. This aligns with Thailand being ranked 6th out of 195 countries for health security, bolstering Thailand’s reputation as Asia’s medical hub.”

Ms. Rungphech Chitanuwat, Group Director – ASEAN at Informa Markets, as the organizer of Medlab Asia and Asia Health, said, “The medical laboratory and healthcare business in Thailand has significantly improved compared to 2023 due to increased demand for medical devices following the expansion of hospitals and healthcare facilities, the rise in the elderly population, and the public’s growing health awareness. These are key factors driving growth in Thailand’s medical device business. Additionally, government support for promoting the medical industry, the introduction of new technologies and innovations enhancing treatment efficiency, collaboration between public and private sectors in research and development, and increased investment in medical infrastructure, all drive the growth of the medical laboratory and medical device industry.”

“Medlab Asia and Asia Health 2024 is the leading platform for the ASEAN medical laboratory and medical device industry, providing unparalleled opportunities for entrepreneurs, industry professionals, and medical personnel to network, connect businesses, share knowledge, and update on the latest medical advancements to enhance business opportunities in the industry and in Asia. This year, over 350 companies from 50 countries will exhibit. Over 10,000 attendees and business matches with potential industry buyers are expected, with an expect to generate value over 1.64 billion baht,” said Rungphech.

Countries participating in showcasing medical products and technologies this year include Singapore, China, South Korea, Taiwan, Japan, Malaysia, Canada, Germany, Poland, Hungary, India, Italy, Australia, the United States, the United Kingdom, the UAE, Switzerland, Sweden, Spain, Thailand, and more. Leading companies such as Dedalus, AGD, AL FAHIM Healthcare Solutions, Autobio, DBC, Healthium, Sekisui Veredus, Snibe, TOP, URIT, WonFo, YHLO, Beacon, DNA-Technology, FAPON, and OneCell Diagnostics will participate.

Products highlight include the DTprime RT-PCR system for DNA/RNA targets analysis is an optimum choice for diagnostic laboratories with high throughput of routine tests, the V-VEIL UP2 is a self-sampling medical device used to collect secretions, various fluids and substances that are in the vaginal cavity and cervix for diagnostic laboratory testing, the Theruptor NXT is a next-generation wound dressing solution aimed at providing optimal wound management which is designed to cater to acute wounds, the OncoIndx offers Comprehensive Genomic Profiling (CGP) across all Solid Tumors. It is a well-validated NGS test to extract therapy information from both tissues as well as blood samples with a Faster Turn Around Time of less than 15 days. Clinalytix Medical AI is an AI assistant for healthcare providers. It predicts and notifies users of each patient’s risk of a set of acute clinical complications, by leveraging the mass of structured and free-text medical data available in each patient’s Electronic Health Record (EHR), and more.

Besides showcasing medical products and technologies, Medlab Asia and Asia Health also hosts scientific academic conferences for professionals to enhance careers and expand knowledge in the ever-changing healthcare world. Renowned speakers from around the world will lead Medlab Asia conferences on topics such as laboratory management, clinical chemistry, molecular diagnostics, clinical microbiology, anatomic pathology, and hematology. Asia Health conferences will cover digital health, future medical practices, hospital management, medical device reimbursement and national health funds, patient safety, radiology, and sterile processing and infection control. Attendees will receive CME, CMTE, CPD, and CNEU continuing education credits. Additionally, there will be seminars for the medical device business sector on doing business in Asia, providing updates on business opportunities in Thailand and Asia for industry entrepreneurs and interested parties.

Interested individuals can visit “Medlab Asia & Asia Health 2024,” showcasing medical laboratory, medical device, and international medical academic conferences, from today until July 12, 2024, at the Queen Sirikit National Convention Center. Visitors can register at https://www.medlabasia.com/.

Hashtag: #medlabasia #asiahealth

https://www.medlabasia.com/
https://x.com/MedlabSeries
https://www.facebook.com/medlabseries

The issuer is solely responsible for the content of this announcement.

About Medlab Asia and Asia Health

As the ASEAN region’s leading medical laboratory and healthcare exhibition and congress, Medlab Asia and Asia Health play a crucial role in developing the value of medical laboratory and healthcare by transforming tomorrow’s diagnostics. They provide a platform for industry leaders, including manufacturers, dealers, and distributors, to share best practices, showcase innovations, and collaborate and network.

GENEVA, SWITZERLAND – Newsaktuell – 10 July 2024 – On July 10, the Friedrich Naumann Foundation for Freedom officially opens its Human Rights Hub in Geneva. The Human Rights Hub will be a hub for the promotion of freedom and human rights worldwide. Journalists, lawyers, activists – many are committed to the universal defense of human rights. In doing so, they often put their own freedom or lives at risk. Freedom is not free – it must be defended by liberal societies and single individuals. Dr. Michaela Lissowsky will serve as the hub’s director.

Anne Brasseur, former President of the Parliamentary Assembly of the Council of Europe and member of the Board of the Friedrich Naumann Foundation for Freedom:

“Geneva is the world capital of human rights and the rule of law. This is where people come together, network, become visible and have their voices heard. All over the world, people are threatened, imprisoned or tortured if they want to express their opinion, argue their case in court or report critically. Standing up for the universal application of human rights every day is at the heart of our mission as the Friedrich Naumann Foundation for Freedom. I am very pleased that the Human Rights Hub in Geneva will be such a place of encounter and joining forces.”

The German Federal Minister of Justice, Dr. Marco Buschmann, who will inaugurate the Human Rights Hub in Geneva, congratulates with the following words:

“Human rights protect people. They protect the individual. At the same time, it is individuals who stand up and fight for these rights. It takes individuals with courage. Because without courage, it wouldn’t have been possible to defend Alexander Navalny in court in Russia. Without courage, you can’t fight corruption or help safeguard the rule of law in Zimbabwe. Without courage, you can’t stand up to those who despise human rights. But even the courageous need help. The Human Rights Hub of the Friedrich Naumann Foundation for Freedom in Geneva will support them in finding that help, winning over fellow campaigners and generating attention. I therefore wish this institution the very greatest of success.”

More information about the work of the Human Rights Hub is available here: https://www.freiheit.org/human-rights-hub-0

Hashtag: #FriedrichNaumannFoundationforFreedom

The issuer is solely responsible for the content of this announcement.

HONG KONG SAR – EQS Newswire – 10 July 2024 – Recently, Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries (Beijing Genetech, Shenzhen Watsin, Dongguan Watsin), the “Group”) is pleased to announce a strategic cooperation with Chongqing Minji Medical Device Co., Ltd. (hereafter “Chongqing Minji”). This partnership expands the Group’s business into the medical aesthetics device sector and enhances its long-term strategy in biopharmaceuticals and medical aesthetics.

In the realm of skincare, amidst the escalating global aging population, rising prevalence of chronic diseases, and growing aspirations for improved aesthetics, there is a surging demand for specialized skincare products post-procedures such as general surgery, cosmetic operations, burns, and accidental injuries. Public data forecasts that by 2026, the market size for medical device dressings and functional skincare products in China will reach CNY 253.8 billion and CNY 623 billion, respectively. This alliance with Chongqing Minji, based on market analysis and growth opportunities, will leverage both parties’ strengths in product registration, R&D, market channels, and brand influence. Together, they aim to develop a new business model combining biopharmaceuticals and medical devices to meet diverse market needs.

As an initial step, Uni-Bio Science Group has secured the exclusive distribution rights nationwide for Chongqing Minji’s flagship product – a hydrogel wound dressing designed for post-skin injury and minimally invasive surgery wound healing. This class II medical device complements the Group’s flagship product, GeneTime® (rEGF recombinant human epidermal growth factor), which is well-established in the domestic market for burn and trauma treatment. The addition of the hydrogel wound dressing further enriches the Group’s product pipeline, providing patients with a full-range solution from treatment to recovery.

Uni-Bio Science Group has also attained the exclusive distribution rights for Chongqing Minji’s soon-to-be-approved collagen liquid dressing, another class II medical device targeting premium demands in medical aesthetics and daily skincare. This aligns with the Group’s self-developed medical aesthetic product pipeline, including fibronectin repair fluids and essence, advancing the group’s integrated strategy of “Medicine + Devices + Cosmetics” for a seamless transition from therapy to beauty, offering consumers a full-cycle skin care solution.

Most notably, both companies will collaborate on developing medical device products based on Uni-Bio Science Group’s proprietary core patented ingredient – Skbrella, a small molecular highly active recombinant human fibronectin. Fibronectin, naturally present in the dermis layer of human skin, boasts remarkable effects in skin repair and nourishment, presenting immense potential in medical aesthetics and premium skincare markets. This joint project aims to develop and launch China’s first batch of class II medical devices utilizing fibronectin, reinforcing the company’s leadership in skincare and medical aesthetics.

Lastly, Uni-Bio Science has the option to deepen its strategic alliance with Chongqing Minji by investing in and potentially acquiring the company within the next 24 months. Seizing this cooperation opportunity, the Group aims to enhance its technological innovation and market expansion in biopharmaceuticals, high-end medical devices, and medical aesthetics. Filled with confidence, the Group aspires to jointly embark on a new chapter in the healthcare industry with Chongqing Minji, introducing more innovative and high-quality products and services to the global skincare market.

Hashtag: #Uni-BioScienceGroupLimited

The issuer is solely responsible for the content of this announcement.

HONG KONG SAR – Media OutReach Newswire – 10 July 2024 – Generali Hong Kong has achieved significant recognition at the Insurance Asia Awards 2024, receiving two prestigious awards that underscore its excellence in social media engagement and product innovation.

The two awards received by Generali Hong Kong include:

• Social Media Initiative of the Year
• New Insurance Product of the Year

The award recognizes Generali Hong Kong’s exceptional performance and strategic approach to its social media channels, which have proven to be highly effective in engaging with its target audience, building brand awareness, and driving business growth. Over the past year, the company has consistently delivered a strong social media presence that has set it apart through creative and engaging content. Through a comprehensive content strategy that combines visually-appealing graphics, thought-provoking insights resonating to the daily lives and needs of the public, and genuine customer interactions, Generali Hong Kong has successfully cultivated a loyal and engaged following across multiple platforms, deeply building its brand presence. Additionally, it underscores our dedication to developing innovative and comprehensive whole of life critical illness insurance products that meet the evolving needs of our customers.

Ms. Ady Law, Chief Distribution and Marketing Officer of Generali Hong Kong, said, “We are honored to receive the Social Media Initiative of the Year award. This recognition reflects our commitment to leveraging digital platforms to connect with our customer and community in impactful and meaningful ways. Our social media strategy is designed to engage and support our customers, ensuring we stay connected and responsive to their needs. Recognizing the pivotal role of digital marketing, we have been diligently investing resources to establish a comprehensive online platform. Our objective is to deliver the most timely and relevant information to the public, thereby cultivating a deeply loyal brand image.

Mr. Ronald Tse, Chief Actuary and Chief Product Officer of Generali Hong Kong, said, “Receiving the New Insurance Product of the Year award is a testament to our team’s dedication to innovation and our commitment to being a Lifetime Partner to our customers. We are committed to offering innovative and comprehensive protection against critical illnesses, providing our customers with financial security and peace of mind.”

The Insurance Asia Awards annually recognize insurance companies across Asia that demonstrate outstanding performance and innovation. These awards acknowledge companies that go beyond the ordinary and significantly influence the lives of their customers with exceptional insurance products, services, and solutions.
Hashtag: #GeneraliHongKong

The issuer is solely responsible for the content of this announcement.

Generali Hong Kong

In 1981, Assicurazioni Generali S.p.A. was first registered as an authorised insurer in Hong Kong, with the business extending into the life insurance sector in 2016 with Generali Life (Hong Kong) Limited. With a combination of local knowledge and Generali Group’s global expertise, we develop unique and innovative life insurance, general insurance, specialty insurance, and employee benefits solutions to meet the needs of our customers.

Generali Group

Generali is one of the largest global insurance and asset management providers. Established in 1831, it is present in over 50 countries in the world, with a total premium income of € 82.5 billion in 2023. With around 82,000 employees serving 70 million customers, the Group has a leading position in Europe and a growing presence in Asia and Latin America. At the heart of Generali’s strategy is its Lifetime Partner commitment to customers, achieved through innovative and personalised solutions, best-in-class customer experience and its digitalised global distribution capabilities. The Group has fully embedded sustainability into all strategic choices, with the aim to create value for all stakeholders while building a fairer and more resilient society.